Novartis AG Cardiovascular Update Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Kerry Ann Holford - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : I have 3, please. On Leqvio, in your associated cost you see in the U.S.? I'm looking at Slide 33, where you mentioned developing trust, injection sense networks, you aiming to do that within each of your target 200 healthcare systems at launch? And if so, is funding that, is that something that you are funding? Or is it in conjunction with these healthcare systems? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MAY 18, 2021 / 3:30PM, NOVN.S - Novartis AG Cardiovascular Update Call And from a promotional perspective, what's the overlap with the Entresto prescribing physician pace? And have you already recruited additional sales or medical reps in order to launch Leqvio, is that required? And then TQJ. I wonder if it's impossible to talk about potentially extending the dosing frequency even further than once monthly is once every 6 months dosing are you similar to Leqvio realistic opportunity? And is there actually any value in a combination with Leqvio I think perhaps the answer is no given that correlation you talked about, we will be interested to hear your thoughts on that. And then finally, a question for Matthew Whitty. You mentioned how CVD was already a sort of ditty target area within your team's long-term objectives here in that new proposition with a nice overlay with that. I would be interested to hear whether there are any other chronic diseases that are on your target list? Perhaps obesity where you might be interested in or indeed actively working on similar partnerships with our metro manufacturer.